I am skeptical of Ozempic, which so many people are running to for reasons of superficial beauty rather than health, and because of some health risks that accompany its usage. However, the following article shows that large numbers of people are open to medical paths that moderate human excess desires, and that the economy will simply adjust to their doing so. Now, various companies are getting rich selling us junk foods and excess calories.
With prescriptions for semaglutide drugs, including Wegovy and Ozempic, on the rise, food sellers are increasingly fielding questions about the possibility of a significant shift in how — or how much — people eat.
The increasingly popular drugs generally work by reducing patients’ appetites. With 1.7% of America’s population prescribed a semaglutide drug in 2023 — up 40-fold in the past five years — that could spell serious trouble for the food industry.
For now, they seem to be thinking about these drugs the way they do food fads: Keeping a sharp eye on consumer behavior, and thinking about ways to capitalize on trends. But they may need to take the rise of this class of drugs more seriously than fad diets, some industry analysts say.
During a Thursday call with Wall Street analysts, Conagra CEO Sean Connolly said that the company will adjust as needed if customers eat less or want different types of food.
“Let’s say they go to smaller portions, then we evolve the innovations, and we design smaller portions,” Connolly said.
“If they switch to different types of nutrients … we switch to different types of nutrients,” he said. “If they change the kind of pack sizes they snack on, we’ll change that.” Conagra has a wide portfolio of food brands, including Healthy Choice, Duncan Hines and Marie Callender’s.
https://us.cnn.com/2023/10/05/invest...ies/index.html
The increasingly popular drugs generally work by reducing patients’ appetites. With 1.7% of America’s population prescribed a semaglutide drug in 2023 — up 40-fold in the past five years — that could spell serious trouble for the food industry.
For now, they seem to be thinking about these drugs the way they do food fads: Keeping a sharp eye on consumer behavior, and thinking about ways to capitalize on trends. But they may need to take the rise of this class of drugs more seriously than fad diets, some industry analysts say.
During a Thursday call with Wall Street analysts, Conagra CEO Sean Connolly said that the company will adjust as needed if customers eat less or want different types of food.
“Let’s say they go to smaller portions, then we evolve the innovations, and we design smaller portions,” Connolly said.
“If they switch to different types of nutrients … we switch to different types of nutrients,” he said. “If they change the kind of pack sizes they snack on, we’ll change that.” Conagra has a wide portfolio of food brands, including Healthy Choice, Duncan Hines and Marie Callender’s.
https://us.cnn.com/2023/10/05/invest...ies/index.html
stlah